Literature DB >> 7622893

Deferoxamine B but not deferoxamine G1 inhibits cytokine production in murine bone marrow macrophages.

I B Autenrieth1, E Bohn, J H Ewald, J Heesemann.   

Abstract

The iron chelator deferoxamine (DFO) B enhances virulence of Yersinia enterocolitica and modulates cellular immune responses. Since cytokines mediate effector mechanisms in resolution of yersiniae from infected tissues, the impact of DFO B and DFO G1 on cytokine production by murine bone marrow macrophages (BMM) was investigated. BMM were stimulated with lipopolysaccharide (LPS) of Salmonella typhimurium or infected with Y. enterocolitica. DFO B inhibited interleukin (IL)-6, IL-12, and tumor necrosis factor (TNF)-alpha mRNA production 4-fold (shown by semiquantitative reverse transcription polymerase chain reaction). TNF-alpha and IL-6 protein production was reduced 50% by DFO B. In contrast, DFO G1 had no effect on cytokine production. Moreover, cytokine production by Yersinia-infected BMM was decreased by plasmid-encoded Yersinia proteins. Thus, plasmid-cured strains induced higher cytokine responses in BMM than did the wild type strain. These results suggest that DFO B acts in a bimodal fashion in yersiniosis: iron supply to the pathogen and immunosuppression of the host.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7622893     DOI: 10.1093/infdis/172.2.490

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  8 in total

1.  Ambiguous role of interleukin-12 in Yersinia enterocolitica infection in susceptible and resistant mouse strains.

Authors:  E Bohn; E Schmitt; C Bielfeldt; A Noll; R Schulte; I B Autenrieth
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

2.  Common and specific characteristics of the high-pathogenicity island of Yersinia enterocolitica.

Authors:  A Rakin; C Noelting; S Schubert; J Heesemann
Journal:  Infect Immun       Date:  1999-10       Impact factor: 3.441

3.  Conjugation of hydroxyethyl starch to desferrioxamine (DFO) modulates the dual role of DFO in Yersinia enterocolitica infection.

Authors:  S Schubert; I B Autenrieth
Journal:  Clin Diagn Lab Immunol       Date:  2000-05

4.  Comparison of the effects of deferiprone versus deferoxamine on growth and virulence of Yersinia enterocolitica.

Authors:  Biliana Lesic; Jeannine Foulon; Elisabeth Carniel
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

5.  Purification of Legiobactin and importance of this siderophore in lung infection by Legionella pneumophila.

Authors:  Kimberly A Allard; Jenny Dao; Prakash Sanjeevaiah; Kessler McCoy-Simandle; Christa H Chatfield; David S Crumrine; Domenic Castignetti; Nicholas P Cianciotto
Journal:  Infect Immun       Date:  2009-04-27       Impact factor: 3.441

6.  Infections in thalassemia and hemoglobinopathies: focus on therapy-related complications.

Authors:  Bianca Maria Ricerca; Arturo Di Girolamo; Deborah Rund
Journal:  Mediterr J Hematol Infect Dis       Date:  2009-12-28       Impact factor: 2.576

7.  Yersinia enterocolitica targets cells of the innate and adaptive immune system by injection of Yops in a mouse infection model.

Authors:  Martin Köberle; Annegret Klein-Günther; Monika Schütz; Michaela Fritz; Susanne Berchtold; Eva Tolosa; Ingo B Autenrieth; Erwin Bohn
Journal:  PLoS Pathog       Date:  2009-08-14       Impact factor: 6.823

8.  Contribution of the major secreted yops of Yersinia enterocolitica O:8 to pathogenicity in the mouse infection model.

Authors:  Konrad Trülzsch; Thorsten Sporleder; Emeka I Igwe; Holger Rüssmann; Jürgen Heesemann
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.